Chimeric antigen receptor targeting CD5 and immune cells expressing same

MYPI2025001828A0Undetermined Publication Date: 2024-04-05GC CELL CORP
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
MYPI2025001828
Authority / Receiving Office
MY · MY
Patent Type
Applications
Current Assignee / Owner
Priority Date
2022-10-05
Filing Date
2023-10-04
Publication Date
2024-04-05

AI Technical Summary

Technical Problem

Current treatments for CD5-positive tumors, such as lymphocytic leukemia, are limited in efficacy and require high doses of immune cells, with existing chimeric antigen receptors (CARs) not effectively enhancing survival and antitumor activity in immune cells.

Method used

A chimeric antigen receptor (CAR) comprising an OX40 ligand intracellular signaling domain and an extracellular antigen binding domain that targets CD5, combined with Interleukin-15 (IL-15), is expressed in immune cells to enhance their survival, proliferation, and antitumor activity, allowing for effective treatment of CD5-positive tumors at lower doses.

Benefits of technology

The CAR-IL-15 fusion protein significantly improves the survival rate, in vitro proliferation, and antitumor activity of immune cells, making them an efficient and effective cell therapy agent for CD5-positive tumors, even at low doses.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure PI2025001828_DRAWING_001
    Figure PI2025001828_DRAWING_001
  • Figure PI2025001828_DRAWING_002
    Figure PI2025001828_DRAWING_002
  • Figure PI2025001828_DRAWING_003
    Figure PI2025001828_DRAWING_003
Patent Text Reader

Abstract

The present invention relates to immune cells co-expressing a chimeric antigen receptor comprising an OX40 ligand as an intracellular signaling domain and IL-15, and a composition for preventing or treating cancer comprising the same as an active ingredient. The immune cells of the present invention not only exhibit synergistic tumor cell-killing activity by co-expression of the chimeric antigen receptor and IL-15, but also have significantly improved viability and in vitro proliferation rate, and thus they may be used as an efficient anticancer cell therapy. In particular, the immune cells of the present invention, when expressing a chimeric antigen receptor targeting CD5, may be applied as an effective therapeutic composition for various CD5-positive tumors, including lymphocytic leukemia.
Need to check novelty before this filing date? Find Prior Art

Description

Chimeric antigen receptor targeting CD5 and immune cells expressing it

[0001] The present invention relates to a chimeric antigen receptor that specifically recognizes CD5 and an immune cell expressing IL-15; and a method for treating a CD5-positive tumor using the same.

[0002]

[0003] Natural killer (NK) cells are lymphocytes that account for approximately 10% of all blood cells and play a crucial role in the immune response. NK cells are a crucial component of the innate immune defense and are suitable for adoptive cellular immunotherapy, which kills cancer cells or cells infected with exogenous pathogens. In the field of cell therapy using T cells, another type of immune cell, active research is being conducted on the technology of introducing chimeric antigen receptors (CARs) into T cells to enhance their specific killing effect against cancer cells expressing specific tumor antigens. CARs are artificial receptors designed to convey antigen specificity to immune cells. They contain an extracellular antigen-binding domain, a transmembrane domain, and an intracellular signaling domain, which are selected to activate immune cells such as T cells and provide specific immunity. The extracellular antigen binding domain comprises a single-chain variable fragment (scFv) that targets an identified tumor antigen, thereby inducing cancer cell-specific immune cell activation that expresses the tumor antigen.

[0004] Meanwhile, OX40 ligand (CD252) is a protein belonging to the TNFR superfamily, and is expressed on antigen-presenting cells (APCs), some natural killer cells, and B cells, and is known to be expressed within hours to days after activation of these cells. OX40 (CD134), the receptor for OX40 ligand, is expressed on T cells, and is known to be expressed on T cells activated by CD28. Expression of OX40 further enhances T cell responses induced by CD28 activation, thereby increasing T cell proliferation, cytokine secretion, and survival.

[0005] CD5 is a type I glycoprotein and a member of the scavenger receptor family. CD5 is expressed by thymocytes, mature T cells, and mature B cells, and is known to be involved in the regulation of lymphocyte activation and differentiation. CD5 attenuates the activation signal of the BCR, allowing B-1 cells to be activated only by highly potent stimuli (e.g., bacterial proteins) and not by normal tissue proteins. CD5 is highly expressed in various hematological malignancies, including acute T-lymphoblastic leukemia and peripheral T-cell lymphoma, as well as solid tumors such as breast cancer and thymic carcinoma, while its expression is suppressed in normal cells. Therefore, it is actively being studied as a therapeutic target for these tumors.

[0006] Numerous papers and patents are referenced and cited throughout this specification. The disclosures of these cited papers and patents are incorporated herein by reference in their entirety to provide a clearer understanding of the state of the art and the scope of the present invention.

[0007]

[0008] The present inventors have conducted extensive research efforts to develop an effective immune cell therapy for various CD5-positive tumors, including lymphocytic leukemia. As a result, when a fusion protein combining a chimeric antigen receptor containing OX40L as an intracellular signaling domain and IL-15 is expressed in immune cells, the survival rate, in vitro proliferation rate, and anti-tumor activity of the immune cells are all significantly enhanced, so that not only can a therapeutically effective amount of cells be easily secured, but the present invention has been completed by discovering that the fusion protein can be used as an effective cell therapy that exhibits excellent anti-cancer effects against CD5-positive tumors even at a low dosage.

[0009] Accordingly, the purpose of the present invention is to provide a chimeric antigen receptor comprising an intracellular signaling domain including an OX40 ligand and an extracellular antigen binding domain binding to CD5; and a fusion protein comprising IL-15.

[0010] Another object of the present invention is to provide a composition for preventing or treating CD5-positive tumors, which comprises immune cells expressing the fusion protein and the same as an active ingredient.

[0011]

[0012] Other objects and advantages of the present invention will become more apparent from the detailed description, claims and drawings below.

[0013]

[0014] According to one aspect of the present invention, the present invention provides a fusion protein comprising:

[0015] (a) a chimeric antigen receptor (CAR) comprising an intracellular signaling domain comprising an OX40 ligand (OX40L); and an extracellular antigen binding domain that binds to CD5; and

[0016] (b) IL(Interleukin)-15.

[0017] The present inventors have conducted extensive research efforts to develop an effective immunotherapy agent for various CD5-positive tumors, including lymphocytic leukemia. As a result, we discovered that when a fusion protein combining a chimeric antigen receptor containing OX40L as an intracellular signaling domain and IL-15 is expressed in immune cells, the survival rate, in vitro proliferation rate, and antitumor activity of the immune cells are all significantly enhanced. This not only facilitates the easy acquisition of a therapeutically effective amount of cells, but also enables the use of an effective cell therapy agent that exhibits excellent anticancer effects against CD5-positive tumors even at low doses.

[0018] As used herein, the term “fusion protein” refers to a recombinant protein molecule in which an amino acid sequence derived from a specific protein or domain is fused with another amino acid sequence derived from a different protein or domain. Each amino acid sequence having different origins may be directly linked within the fusion protein, or may be linked via a linker sequence, a tag sequence, a self-cleaving sequence, or a combination thereof. The fusion protein of the present invention may be a fusion protein in which the amino acid sequence of a chimeric antigen receptor (CAR) and the amino acid sequence of an IL-15 protein are directly linked, or may be indirectly linked via a linker, a tag, a self-cleaving sequence, or a combination thereof, and may be produced by a recombinant technique known in the art or expressed in a target cell.

[0019] In this specification, the term “extracellular antigen binding domain” refers to a domain that, when a chimeric antigen receptor is expressed in a target cell (e.g., an immune cell), is located in the extracellular portion and specifically recognizes the target antigen, thereby activating the apoptotic activity of the immune cell specifically in the target cell (e.g., a cancer cell), and may be an antigen-binding fragment of an antibody, such as an Fc receptor or a single-chain variable fragment (ScFv). Therefore, the term “extracellular antigen binding domain” in the present invention is used with the same meaning as “extracellular domain”, “antigen recognition fragment” or “antigen binding fragment”.

[0020] According to a specific embodiment of the present invention, the extracellular antigen binding domain is an antigen binding fragment of an anti-CD5 antibody.

[0021] The term “antibody” as used herein means an antibody against the CD5 protein, which specifically recognizes and binds to a specific epitope thereof, and includes not only a complete full-length antibody form but also an antigen-binding fragment (antibody fragment) of the antibody molecule.

[0022] A complete antibody has two full-length light chains and two full-length heavy chains, each light chain linked to a heavy chain by a disulfide bond. The heavy chain constant regions are of the gamma (γ), mu (μ), alpha (α), delta (δ), and epsilon (ε) types, and are subclassed into gamma1 (γ1), gamma2 (γ2), gamma3 (γ3), gamma4 (γ4), alpha1 (α1), and alpha2 (α2). The light chain constant regions are of the kappa (κ) and lambda (λ) types.

[0023] The term “antigen-binding fragment of an antibody” as used herein means a fragment possessing antigen-antibody binding function within the entire antibody molecule, and specifically includes a Fab fragment, an F(ab') fragment, an F(ab')2 fragment, and an Fv fragment.

[0024] Among antibody fragments, Fab consists of the variable regions of the light and heavy chains, the constant region of the light chain, and the first constant region of the heavy chain (C H1 ) has one antigen binding site. Fab' has a heavy chain C H1 It differs from Fab in that it has a hinge region containing one or more cysteine ​​residues at the C-terminus of the domain. F(ab')2 antibodies are produced when the cysteine ​​residues in the hinge region of Fab' form a disulfide bond. Fv is the smallest antibody fragment that has only a heavy chain variable region and a light chain variable region. A two-chain Fv (two-chain Fv) has a heavy chain variable region and a light chain variable region linked non-covalently, and a single-chain Fv (single-chain Fv, ScFv) has a heavy chain variable region and a single chain variable region covalently linked through a peptide linker or directly linked at the C-terminus, so that it can form a dimer-like structure like a two-chain Fv. These antibody fragments can be obtained using proteolytic enzymes (for example, restriction digestion of a whole antibody with papain yields a Fab, and digestion with pepsin yields an F(ab')2 fragment), and can also be produced through genetic recombination technology.

[0025] More specifically, the antigen-binding fragment of the antibody used in the present invention is ScFv of an anti-CD5 antibody.

[0026] The term “heavy chain” as used herein refers to a variable region domain V comprising an amino acid sequence having sufficient variable region sequence to confer specificity to an antigen. H and three constant region domains C H1 , CH2 and C H3 It refers to both the full-length heavy chain and fragments thereof. In this specification, the term “CDR (complementarity determining region)” refers to the amino acid sequence of the hypervariable region of the immunoglobulin heavy and light chains. The heavy chain (HCDR1, HCDR2, and HCDR3) and the light chain (LCDR1, LCDR2, and LCDR3) each contain three CDRs, which provide the major contact residues for binding of the antibody to an antigen or epitope.

[0027] The scope of the antibodies or antibody fragments of the present invention includes variants having conservative amino acid substitutions in the CDR regions. In addition, the antibodies or antibody fragments of the present invention may include variants of the amino acid sequences set forth in the attached sequence listing, as long as they can specifically recognize phosphorylated PLCγ2. For example, additional changes may be made to the amino acid sequence of the antibody to further improve the binding affinity and / or other biological properties of the antibody. Such modifications include, for example, deletions, insertions, and / or substitutions of amino acid sequence residues of the antibody. Such amino acid mutations are made based on the relative similarity of amino acid side-chain substituents, such as hydrophobicity, hydrophilicity, charge, size, etc. Analysis of the size, shape, and type of amino acid side-chain substituents reveals that arginine, lysine, and histidine are all positively charged residues; alanine, glycine, and serine have similar sizes; and phenylalanine, tryptophan, and tyrosine have similar shapes. Therefore, based on these considerations, arginine, lysine and histidine; alanine, glycine and serine; and phenylalanine, tryptophan and tyrosine can be considered biologically functional equivalents.

[0028] Amino acid exchanges in proteins that do not alter the overall activity of the molecule are well known in the art (H. Neurath, R.L. Hill, The Proteins, Academic Press, New York, 1979). The most common exchanges are between amino acid residues Ala / Ser, Val / Ile, Asp / Glu, Thr / Ser, Ala / Gly, Ala / Thr, Ser / Asn, Ala / Val, Ser / Gly, Thr / Phe, Ala / Pro, Lys / Arg, Asp / Asn, Leu / Ile, Leu / Val, Ala / Glu, and Asp / Gly.

[0029] Considering the mutations having the above-described biological equivalent activity, the antigen recognition fragment of the antibody of the present invention or the nucleic acid molecule encoding it is interpreted to also include a sequence showing substantial identity with the sequence described in the sequence listing. The above-described substantial identity means a sequence showing at least 80% homology, in one specific example 85% homology, in another specific example 90% homology, in another specific example 95% homology, and in another specific example 99% homology, when the sequence of the present invention and any other sequence are aligned to the greatest extent possible and the aligned sequence is analyzed using an algorithm commonly used in the art. Alignment methods for sequence comparison are known in the art (Smith and Waterman, Adv. Appl. Math. (1981) 2:482; Huang et al. Comp. Appl. BioSci. (1992) 8:155-65 and Pearson et al. Meth. Mol. Biol. (1994) 24:307-31).

[0030]

[0031] According to a specific embodiment of the present invention, the extracellular antigen binding domain comprises a heavy chain variable region including an HCDR1 having an amino acid sequence of sequence number 26, an HCDR2 having an amino acid sequence of sequence number 28, and an HCDR3 having an amino acid sequence of sequence number 30.

[0032] More specifically, the heavy chain variable region comprises the amino acid sequence of sequence number 32.

[0033] According to a specific embodiment of the present invention, the extracellular antigen binding domain additionally includes a light chain variable region including LCDR1 having an amino acid sequence of Sequence Listing No. 34, LCDR2 having an amino acid sequence of Sequence Listing No. 36, and LCDR3 having an amino acid sequence of Sequence Listing No. 38.

[0034] More specifically, the light chain variable region comprises the amino acid sequence of sequence number 40.

[0035] Most specifically, the extracellular antigen binding domain used in the present invention comprises the amino acid sequence of sequence number 9.

[0036]

[0037] According to a specific embodiment of the present invention, the intracellular signaling domain additionally comprises one or more domains selected from the group consisting of CD28, CD3-zeta, OX40, and 4-1BB. More specifically, the intracellular signaling domain additionally comprises CD28 and CD3-zeta.

[0038] Most specifically, the intracellular signaling domain comprises CD28, OX40L and CD3-zeta in that order from the cell membrane to the intracellular direction.

[0039]

[0040] According to a specific embodiment of the present invention, the fusion protein additionally comprises a self-cleaving peptide positioned between the chimeric antigen receptor and the IL-15. More specifically, the self-cleaving peptide comprises the amino acid sequence of Sequence Listing No. 21.

[0041] According to the present invention, the amino acid sequence of Sequence Listing No. 21 is the amino acid sequence of a T2A self-cleaving peptide. The T2A self-cleaving peptide is a type of 2A-self-cleaving peptide that cleaves a full-length protein into short peptide fragments by inducing ribosomal skipping during the intracellular protein translation process, and includes 18 amino acids (EGRGSLLTCGDVEENPGP) of Sequence Listing No. 21. According to one embodiment of the present invention, a GSG (Gly-Ser-Gly) sequence may be added to the N-terminus to enhance the self-cleavage activity by the amino acid sequence of Sequence Listing No. 21. The chimeric antigen receptor of the present invention and IL-15 may be cleaved and expressed by the T2A self-cleaving peptide of the present invention.

[0042]

[0043] According to another aspect of the present invention, the present invention provides a nucleic acid molecule encoding the fusion protein of the present invention described above.

[0044] In this specification, the term “nucleic acid molecule” has a comprehensive meaning including DNA (gDNA and cDNA) and RNA molecules, and nucleotides, which are the basic structural units of nucleic acid molecules, include not only natural nucleotides but also analogues in which sugar or base moieties are modified (Scheit, Nucleotide Analogs, John Wiley, New York (1980); Uhlman and Peyman, Chemical Reviews, 90:543-584 (1990)). The nucleic acid molecule of the present invention can be introduced into a target cell by being inserted into a gene delivery vehicle in order to express the fusion protein of the present invention described above in a target cell, for example, an immune cell.

[0045] As used herein, the term "express" means artificially introducing a gene using a gene vector to cause a target cell to express an exogenous gene or to increase the natural expression level of an endogenous gene, thereby making the gene replicable within the target cell as an extrachromosomal element or through chromosomal integration. Therefore, the term "expression" has the same meaning as "transformation," "transfection," or "transduction."

[0046] As used herein, the terms "gene delivery vehicle" or "gene delivery system" refer to any means of transporting a gene into a cell, and gene delivery is synonymous with transduction of the gene into the cell. At the cellular or tissue level, gene delivery is synonymous with gene spread. Therefore, the gene delivery system of the present invention may be described as a gene penetration system or a gene spread system.

[0047] To prepare the gene delivery system of the present invention, the nucleotide sequence of the present invention is preferably operably linked to a suitable expression control sequence within a suitable expression construct. As used herein, the term “operably linked” refers to a functional linkage between a nucleic acid expression control sequence (e.g., a promoter, a signal sequence, or an array of transcription factor binding sites) and another nucleic acid sequence, whereby the control sequence regulates the transcription and / or translation of the other nucleic acid sequence. The promoter linked to the target gene of the present invention is capable of operating in animal cells, more specifically mammalian cells, and most specifically immune cells to control transcription of the target gene, and includes promoters derived from mammalian viruses and promoters derived from the genome of mammalian cells, such as, but not limited to, the CMV (mammalian cytomegalovirus) promoter, the adenovirus late promoter, the vaccinia virus 7.5K promoter, the SV40 promoter, the tk promoter of HSV, the RSV promoter, the EF1 alpha promoter, the metallothionine promoter, the beta-actin promoter, the promoter of the human IL-2 gene, the promoter of the human IFN gene, the promoter of the human IL-4 gene, the promoter of the human lymphotoxin gene, and the promoter of the human GM-CSF gene.

[0048] The nucleotide sequence of the target gene can be applied to any gene delivery system used for conventional gene introduction, for example, plasmids, adenoviruses (Lockett LJ, et al., Clin. Cancer Res. 3:2075-2080(1997)), adeno-associated viruses (AAV, Lashford LS., et al., Gene Therapy Technologies, Applications and Regulations Ed. A. Meager, 1999), retroviruses (Gunzburg WH, et al., Retroviral vectors. Gene Therapy Technologies, Applications and Regulations Ed. A. Meager, 1999), lentiviruses (Wang G. et al., J. Clin. Invest. 104(11):R55-62(1999)), herpes simplex viruses (Chamber R., et al., Proc. Natl. Act . Sci USA92:1411-1415(1995)), vaccinia virus (Puhlmann M. et al., Human Gene Therapy10:649-657(1999)), liposomes (Methods in Molecular Biology, 199, SC Basu and M. Basu (Eds.), Human Press 2002) or niosomes.

[0049] According to a specific embodiment of the present invention, the gene delivery vehicle used in the present invention is a viral vector. More specifically, the virus is selected from the group consisting of lentivirus, adenovirus, adeno-associated virus (AAV), retrovirus, herpes simplex virus, and vaccinia virus, and most specifically, lentivirus.

[0050] A list of base sequences of nucleic acid molecules encoding the entire fusion protein of the present invention or each domain constituting the same is summarized in Table 2 below.

[0051] According to another aspect of the present invention, the present invention provides an immune cell expressing the nucleic acid molecule of the present invention described above.

[0052] As used herein, the term "immune cell" refers to any cell involved in the initiation or promotion of an immune response, and more specifically, refers to an immune effector cell. Immune cells include, but are not limited to, T cells, B cells, natural killer (NK) cells, natural killer T (NKT) cells, and mast cells. More specifically, the immune cell is a natural killer cell.

[0053] According to another aspect of the present invention, the present invention provides an immune cell expressing:

[0054] (a) a chimeric antigen receptor (CAR) comprising an intracellular signaling domain comprising an OX40 ligand (OX40L); and an extracellular antigen binding domain that binds to CD5; and

[0055] (b) IL(Interleukin)-15.

[0056] Since the immune cells used in the present invention have already been described above, their description is omitted to avoid excessive duplication.

[0057] The immune cell of the present invention may express the chimeric antigen receptor and IL-15 in the form of a single fusion protein in which they are linked to each other, as described in one embodiment of the present invention described above, or may express the chimeric antigen receptor and IL-15 as individual protein molecules without being linked, as in this embodiment. In this case, the chimeric antigen receptor and IL-15 may be co-transfected into the immune cell by inserting the nucleic acid molecules encoding them into separate gene carriers, or may be inserted together into a single gene carrier and transfected.

[0058] According to a specific embodiment of the present invention, the immune cells used in the present invention are natural killer cells, and more specifically, the natural killer cells are natural killer cells that are cultured for 23 to 35 days, even more specifically for 25 to 33 days, and most specifically for 28 to 30 days, and then frozen and thawed.

[0059] The term “culture” in this specification means inducing cells to grow and proliferate while maintaining biological activity in an in vitro environment such as a culture medium.

[0060] The term “culture medium” as used herein encompasses a mixture containing essential elements for cell growth and proliferation, such as sugars, amino acids, minerals, and other nutrients, for effectively inducing and promoting cell growth and proliferation in vitro. Cell culture media can be optimized according to the type of specific cell, its phenotype, and culture characteristics, and include, for example, a basic culture medium formulated to support cell growth, a culture medium formulated to promote recombinant protein production from cells, and a concentrated medium made by highly concentrating nutrients.

[0061] As used herein, the term “freezing” or “cryopreservation” refers to the stable maintenance of cells at low temperatures, specifically at ultra-low temperatures of -80°C to -200°C, for a short or long period of time. Mutations typically occur in cells during culture at a rate of about one in ten thousand. If cells are passaged for a long period of time, they may transform into a cell population different from the original, or their inherent biological activity and function may be lost. Furthermore, the risk of infection by mycoplasma and other pathogens increases in proportion to the passage period. Therefore, freezing cells is widely used to preserve their unique characteristics. The present inventors have discovered that in immune cells, particularly natural killer cells with low gene transfer efficiency using lentiviral vectors, gene transfer rates and cell death rates are significantly improved when freezing is performed after an appropriate period of culture. Therefore, unlike cryopreservation, which is performed for the purpose of long-term preservation of cells, the freezing step performed in the present invention may be performed only for a short period of time.

[0062] Cell freezing can be performed by treating cells with a cryoinhibitor, which minimizes cell damage caused by the formation of ice crystals and the resulting ionic and osmotic imbalances that inevitably accompany freezing and thawing. Freezing media may include, for example, dextran, albumin, and / or DMSO to enhance cell safety and stability during freezing.

[0063] As used herein, the term "thawing" refers to the process of raising the temperature of frozen or cryopreserved cells until they become soft, viable cells, allowing them to resume vital activity. Thawing is typically accomplished quickly by removing ultra-low-temperature frozen cells from a liquid nitrogen tank or similar and placing them in a 37°C constant-temperature water bath.

[0064] Since the freezing and thawing process of the present invention is intended to improve the gene introduction efficiency of cells and to enhance the killing activity of pathogenic cells rather than to store cells for a long period of time, the freezing and thawing process may be initiated immediately after freezing is completed without a time interval, or an appropriate time gap may be established between the freezing and thawing processes as needed.

[0065]

[0066] According to another aspect of the present invention, the present invention provides a composition for preventing or treating a CD5 positive tumor, comprising the immune cell of the present invention as an active ingredient.

[0067] According to another aspect of the present invention, the present invention provides a method for preventing or treating a CD5 positive tumor, comprising administering to a subject the immune cells of the present invention described above.

[0068] As used herein, the term “treatment” means (a) suppressing the development of a disease, condition, or symptom; (b) alleviating the disease, condition, or symptom; or (c) eliminating the disease, condition, or symptom. When an immune cell into which the target gene of the present invention (a nucleic acid molecule encoding a chimeric antigen receptor that specifically recognizes CD5) has been introduced is administered to a subject, it induces the death of CD5-positive cancer cells, thereby suppressing the development of symptoms caused by various CD5-positive tumors, including lymphocytic leukemia, or eliminating or alleviating them. Therefore, the composition of the present invention may be a cell therapy composition on its own for a disease, or may be administered together with other pharmacological ingredients and used as an adjuvant treatment for the disease. Accordingly, the terms “treatment” or “therapeutic agent” as used herein include the meaning of “adjuvant treatment” or “adjuvant treatment agent.”

[0069] As used herein, the term “administration” or “administer” refers to directly injecting a therapeutically effective amount of the composition of the present invention into a subject so that the same amount is formed in the body of the subject.

[0070] In the present invention, the term “therapeutically effective amount” means the content of the composition contained in an amount sufficient to provide a therapeutic or preventive effect to an individual to whom the composition of the present invention is to be administered, and includes “prophylactically effective amount”.

[0071] The term “subject” as used herein includes, without limitation, a human, mouse, rat, guinea pig, dog, cat, horse, cow, pig, monkey, chimpanzee, baboon, or rhesus macaque. Specifically, the subject of the present invention is a human.

[0072] The term “CD5-positive tumor” as used herein refers to a solid tumor or hematological cancer in which CD5 is measurably overexpressed compared to normal cells or CD5-negative tumors. CD5 is expressed in 85% of T-lineage acute lymphoblastic leukemia (T-ALL) and 75% of peripheral T-cell lymphomas, and is a transmembrane receptor protein that is highly expressed in mantle cell lymphoma, chronic lymphocytic leukemia (B-CLL), and hairy cell leukemia. Its expression is suppressed in normal cells, and it is used as an effective therapeutic and diagnostic target for tumors.

[0073] CD5-positive tumors that can be prevented or treated with the composition of the present invention include, but are not limited to, hematological cancers such as leukemia, lymphoma, and multiple myeloma, and solid cancers such as breast cancer and thymic cancer, and include all malignant tumors that can be specifically recognized by the immune cells of the present invention by expressing CD5 at a measurable level on the surface of tumor cells.

[0074] More specifically, the CD5 positive tumor is T lymphocytic leukemia, and more specifically, acute T lymphocytic leukemia.

[0075]

[0076] The immune cells of the present invention, specifically natural killer cells, may be included in an amount of 10 to 95% by weight of the total weight of a composition for the prevention or treatment of CD5-positive tumors, including the immune cells as an active ingredient. Furthermore, the composition of the present invention may be formulated by additionally including one or more anticancer pharmacological ingredients exhibiting the same or similar function as the natural killer cells, in addition to the pharmacological ingredient.

[0077] The dosage of the above composition can be adjusted according to various factors including the type of CD5 positive tumor, the severity of the disease, the type and content of the active ingredient and other ingredients included in the composition, the type of formulation, and the patient's age, weight, general health, sex, and diet, the time of administration, the route of administration, and the secretion rate of the composition, the treatment period, and concurrently used drugs. However, for a desirable effect, the dosage of the natural killer cells according to the present invention is, for example, 0.01 x 10 7 cells / kg to 1.0 x 10 9 cells / kg, and may be 0.5 x 10 7 cells / kg to 1.0 x 10 8 It can be cells / kg.

[0078] Additionally, the composition of the present invention can be administered to a subject using various cell therapy injection methods known in the art. The route of administration can be appropriately selected by those skilled in the art, taking into account factors such as the method of administration, the volume of the body fluid, and its viscosity. For example, the composition of the present invention can be administered parenterally, specifically intravenously, subcutaneously, or intraperitoneally, and most specifically intravenously.

[0079]

[0080] The features and advantages of the present invention are summarized as follows:

[0081] (a) The present invention provides a composition for preventing or treating cancer, comprising an immune cell co-expressing IL-15 and a chimeric antigen receptor including an OX40 ligand as an intracellular signaling domain, and the same as an active ingredient.

[0082] (b) The immune cells of the present invention not only exhibit synergistic tumor cell killing activity through co-expression of the chimeric antigen receptor and IL-15, but also significantly improve survival rate and in vitro proliferation rate, and thus can be usefully used as an efficient anticancer cell therapy agent.

[0083] (c) In particular, when the immune cells of the present invention express a chimeric antigen receptor targeting CD5, they can be utilized as an effective therapeutic composition for various CD5-positive tumors, including lymphocytic leukemia.

[0084]

[0085] FIG. 1 is a diagram showing the structure of a chimeric antigen receptor (CAR) used in the present invention, and schematically shows a control structure containing only GFP, a third-generation CAR structure containing CD28, OX40L, and CD3ζ as signaling domains, a structure lacking a signaling domain and containing only an IL-15 domain, and a fourth-generation CAR structure in which an IL-15 domain is additionally linked to the third-generation CAR structure.

[0086] Figure 2 is a diagram showing the results of measuring the survival rate and proliferation (fold expansion) of third-generation CAR-NK cells and fourth-generation CAR-NK cells in the absence of IL-2 cytokine.

[0087] Figure 3 is a drawing showing the results of measuring the tumor cell killing ability of third-generation CAR-NK cells and fourth-generation CAR-NK cells against HER2-positive tumor cell lines, HCC1954 and SKOV.

[0088] Figure 4 is a drawing showing the results of observing changes in the amount of IFN-γ secreted by third-generation CAR-NK cells and fourth-generation CAR-NK cells in contact with HER2-positive tumor cell lines HCC1954 and SKOV.

[0089] Figure 5 is a schematic diagram summarizing the NK cell culture process in the present invention.

[0090] Figure 6 shows the results of measuring the CD5 CAR expression pattern in natural killer cells (MCB) cultured and frozen for 28 to 30 days through the upper process of Figure 5, and natural killer cells (DP) cultured and frozen for 42 to 44 days through the lower process of Figure 1.

[0091] Figure 7 shows the results of analyzing cell phenotypes based on the expression patterns of each surface marker of MCB and DP.

[0092] Figure 8 shows the results of FACS analysis measuring CD5 protein expression in each tumor cell line of K562, NALM6, CCRF-CEM, RPMI-8402_Luc, NALM6-NucLight, CCRF-CEM-NucLight, and RPMI-8402-NucLight.

[0093] Figure 9 shows the results of measuring the expression levels of CD107a, IFN-γ, and TNFα (n=3) in CBNK or CD5 CAR-NK co-cultured with various tumor cell lines.

[0094] Figure 10 is a schematic diagram showing a culture method for confirming the tumor cell killing ability of CD5 CAR transduced cells.

[0095] Figure 11 shows the results confirming the killing ability of NK cells against CD5 positive and CD negative tumor cells.

[0096] Figure 12 shows the results of measuring the average IFN-γ secretion amount (pg / mL) of three donors.

[0097] Figure 13 shows the results of measuring the average amount of IL-15 secreted (pg / mL) by NK cells co-cultured with each target cell.

[0098] Figure 14 shows the results of long-term tumor cell killing ability confirmed after co-culturing CD5 positive and CD5 negative tumor cells with CD5 CAR-NK cells for 96 hours.

[0099] Figure 15 shows the results of measuring the survival rate (%) for up to 140 days after tumor transplantation in each experimental group according to each administered substance.

[0100] Figure 16 shows the animal bioimaging results up to 112 days after tumor transplantation and NK cell injection of the present invention.

[0101] Figure 17 shows the results of measuring the image signal value (photon / s) over time up to 35 days after tumor transplantation.

[0102] Figure 18 shows the results of measuring the survival rate (%) for up to 133 days following injection of NK cells of the present invention after tumor transplantation into experimental animals.

[0103] Figure 19 shows the results of bioimaging for up to 126 days following injection of NK cells of the present invention after tumor transplantation into an experimental animal.

[0104]

[0105] Example

[0106] Example 1: Production of CAR-NK cells expressing a third-generation chimeric antigen receptor (CAR) and fourth-generation CAR-NK cells simultaneously expressing a third-generation chimeric antigen receptor and an IL-15 domain.

[0107] The structure of the chimeric antigen receptor (CAR) used in the present invention is summarized in Table 1 below.

[0108] CAR type abbreviation signal sequence ECD hinge TM signal-1 signal-2 signal-3 2A peptide 3rd generation HER2 CAR CD8α anti-HER2 scFvCD8αCD28CD28OX40LCD3z--TruncatedHER2 CAR(t)-IL-15CD8α anti-HER2 scFvCD8αCD28---T2AIL-15 4th generation HER2 CAR-IL-15CD8α anti-HER2 scFvCD8αCD28CD28OX40LCD3zT2AIL-15 4th generation CD5 CAR CD8α anti-CD5 scFvCD8αCD28CD28OX40LCD3zT2AIL-15

[0109] To confirm the synergistic effect of co-expression of the OX40L-containing CAR of the present invention and IL-15, a HER2 CAR (3rd generation) was produced, which comprises a signal sequence domain of CD8a (nucleotides 890-952, GenBank NM 001768.6); an anti-HER2 scFv sequence (VH-(GGGGS)3-VL domain); a hinge domain derived from human CD8α (nucleotides 1292-1435, GenBank NM 001768.6); a transmembrane and intracellular signaling domain derived from CD28 (nucleotides 679-882, GenBank NM 006139.3); and an intracellular signaling domain derived from CD252 (nucleotides 141-206, GenBank NM 003326.4); And it has a structure in which the intracellular signaling domain (nucleotides 299-634 of CD3z, GenBank NM000734.3) and the stop codon TGA are sequentially linked. HER2 CAR(t)-IL-15 has a signal sequence domain of CD8α (nucleotides 890-952 of CD8α, GenBank NM 001768.6); an anti-HER2 scFv sequence (VH-(GGGGS)3-VL domain); a hinge domain derived from human CD8α (nucleotides 1292-1435 of CD8α, GenBank NM 001768.6); a transmembrane domain derived from CD28 (nucleotides 679-759 of CD28, GenBank NM 006139.3); a T2A self-cleaving peptide sequence linked with glycine (G)-serine (S)-glycine (G); It has a structure in which the human IL-15 sequence (nucleotides 375-860, GenBank NM000585.4) and the stop codon TGA are sequentially linked.

[0110] HER2 CAR-IL-15 (4th generation) comprises a signal sequence domain of CD8α (nucleotides 890-952, GenBank NM 001768.6); an anti-HER2 scFv sequence (VH-(GGGGS)3-VL domain); a hinge domain derived from human CD8α (nucleotides 1292-1435, GenBank NM 001768.6); a transmembrane and intracellular signaling domain derived from CD28 (nucleotides 679-882, GenBank NM 006139.3); an intracellular signaling domain derived from CD252 (nucleotides 141-206, GenBank NM 003326.4); and an intracellular signaling domain derived from CD3z (nucleotides 299-634, GenBank NM000734.3); T2A self-cleaving peptide sequence linked to GSG; has a structure in which the human IL-15 sequence (nucleotides 375-860, GenBank NM000585.4) and the stop codon TGA are sequentially linked.

[0111] CD5 CAR (4th generation) comprises a signal sequence of CD8α (nucleotides 890-952, GenBank NM 001768.6); an anti-CD5 scFv domain (VH-(GGGGS)3 linker-VL); a hinge domain derived from CD8α (nucleotides 1292-1435, GenBank NM 001768.6); a transmembrane and intracellular signaling domain derived from CD28 (nucleotides 679-882, GenBank NM 006139.3); a CD252-derived intracellular signaling domain (nucleotides 141-206, GenBank NM 003326.4); and a CD3z-derived intracellular signaling domain (nucleotides 299-634, GenBank NM000734.3). T2A self-cleaving peptide sequence linked to GSG; has a structure in which the human IL-15 sequence (nucleotides 375-860, GenBank NM000585.4) and the stop codon TGA are sequentially linked.

[0112] The base sequence and amino acid sequence of each domain included in the chimeric antigen receptor produced in the present invention are summarized in Table 2 below.

[0113] Sequence NumberSequence NameDescription of Sequence 1CD8a NucleotidesSignal sequence of CD8a (nucleotides 890-952, GenBank NM 001768.6)2CD8a Nucleotide Codon OptimizationCodon optimized sequence of SEQ ID NO: 13CD8a Amino AcidsAmino acid sequence corresponding to SEQ ID NO: 1 and 24Anti-HER2 scFv NucleotidesAnti-HER2 scFv sequence VH-(GGGGS)3 linker-VL domain5Anti-HER2 scFv amino acidsAmino acid sequence corresponding to SEQ ID NO: 46Anti-CD5 scFv (VH-GS3-VL) NucleotidesAnti-CD5 scFv sequence VH-(GGGGS)3 linker-VL domain7Anti-CD5 scFv (VH-GS3-VL) amino acidsAmino acid sequence corresponding to SEQ ID NO: 68CD8a NucleotidesHinge domain from human CD8a (nucleotides 1292-1435, GenBank NM 001768.6)9 CD8a nucleotide codon optimization Codon-optimized sequence of SEQ ID NO: 810 CD8a amino acid amino acid sequence of SEQ ID NO: 8 and 911 CD28 nucleotides Transmembrane and intracellular signaling domain from CD28 (nucleotides 679-882, GenBank NM 006139.3)12 CD28 nucleotide codon optimization Codon-optimized sequence of SEQ ID NO: 1113 CD28 amino acid amino acid sequence of SEQ ID NO: 11 and 1214 CD252 nucleotides Intracellular signaling domain from CD252 (nucleotides 141-206, GenBank NM 003326.4)15 CD252 nucleotide codon optimization Codon-optimized sequence of SEQ ID NO: 1416 CD252 Amino acid sequence of amino acid sequence numbers 14 and 1517CD3z nucleotidesCD3z-derived intracellular signaling domain (nucleotides 299-634, GenBank NM000734.3)18CD3z nucleotide codon optimizationCodon optimized sequence of SEQ ID NO: 1719CD3z amino acid amino acid sequence of SEQ ID NO: 17 and 1820T2A nucleotideT2A self-cleaving peptide sequence21T2A amino acid amino acid sequence of SEQ ID NO: 2022IL-15 nucleotidehuman IL-15 sequence (nucleotides 375-860, GenBank NM000585.4) 23 IL-15 nucleotide codon optimization Codon-optimized sequence of SEQ ID NO: 22 24 IL-15 amino acid sequence of SEQ ID NO: 22 and 23 25 Anti-CD5 scFv HCDR1 nucleotide HCDR1 coding nucleotide of anti-CD5 scFv 26 Anti-CD5 scFv HCDR1 amino acid sequence of SEQ ID NO: 25 27 Anti-CD5 scFv HCDR2 nucleotide HCDR2 coding nucleotide of anti-CD5 scFv 28 Anti-CD5 scFv HCDR2 amino acid sequence of SEQ ID NO: 27 29 Anti-CD5 scFv HCDR3 nucleotide HCDR3 coding nucleotide of anti-CD5 scFv 30 Anti-CD5 scFv HCDR3 amino acid sequence of SEQ ID NO: 29 31 Anti-CD5 scFv heavy chain variable region nucleotide Anti-CD5 Nucleotides encoding the entire heavy chain variable region of scFv 32 Amino acid sequence of anti-CD5 scFv heavy chain variable region amino acid sequence number 31 33 Nucleotides encoding LCDR1 of anti-CD5 scFv 34 Nucleotides encoding LCDR1 of anti-CD5 scFv 35 Nucleotides encoding LCDR2 of anti-CD5 scFv 36 Nucleotides encoding LCDR2 of anti-CD5 scFv 35 Amino acid sequence of anti-CD5 scFv LCDR2 amino acid sequence number 37 Nucleotides encoding LCDR3 of anti-CD5 scFv 38 Nucleotides encoding LCDR3 of anti-CD5 scFv 37 Amino acid sequence of anti-CD5 scFv LCDR3 amino acid sequence number 39 Nucleotides encoding the entire light chain variable region of anti-CD5 scFv 40 Nucleotides encoding anti-CD5 scFv Amino acid sequence of light chain variable region amino acid sequence number 39.

[0114] IL-15 is known to be a cytokine that activates NK cells and contributes to their survival and proliferation. Therefore, the present inventors introduced a soluble form of IL-15 protein into a chimeric antigen receptor comprising an scFv fragment and a signaling domain that specifically recognizes HER2 to determine whether co-expression of IL-15 in NK cells expressing a chimeric antigen receptor improves survival and in vivo persistence, and evaluated its efficacy (Fig. 1). By linking the anti-HER2 scFv fragment and signaling domain with the soluble IL-15 domain using the T2A system, NK cells expressing a bicistronic form of the chimeric antigen receptor were generated, and these were named “4th generation CAR-NK cells” (Fig. 1, “d”). As controls, third-generation CAR-NK cells expressing a chimeric antigen receptor that expresses an anti-HER2 scFv fragment and a signaling domain but not an IL-15 domain (“b” in Fig. 1), and NK cells expressing an anti-HER2 scFv fragment but lack an intracellular signaling domain and express an IL-15 domain (“c” in Fig. 1, designated CAR(t)-IL-15-NK cells) were also produced. A gene expressing GFP was used as a control (“a” in Fig. 1).

[0115]

[0116] Example 2: Survival and growth results of third- and fourth-generation CAN-NK cells.

[0117] NK cells derived from umbilical cord blood were cultured, and each gene was introduced on the 7th day. From the 22nd day of culture, IL-2 was not added to the culture medium, and cell viability and growth were observed. Except for the 4th generation CAR-NK cells and CAR(t)-NK cells, the cell groups showed a significant decrease in viability from the time point when IL-2 was not added, no further growth occurred, and most cells died on the 41st day of culture (Fig. 2). Only CAR-NK cells with a structure containing the IL-15 domain maintained viability and growth, and it was confirmed that the secreted IL-15 contributed to the survival and proliferation of NK cells.

[0118]

[0119] Example 3: Comparison of the efficacy of third- and fourth-generation CAR-NK cells and synergistic effects by the IL-15 domain.

[0120] 3-1) Evaluation of tumor cell killing ability

[0121] To confirm the efficacy of the fourth-generation CAR-NK cells, we co-cultured them with tumor cell lines expressing HER2 to examine the cytotoxicity of NK cells. Two tumor cell lines expressing HER2 (HCC1954, SKOV3) were used as targets, and RFP was expressed so that the fluorescent signal disappears upon cell death. Various types of NK cell populations and tumor cell lines were cultured without the addition of IL-2 from the 22nd day of culture, and then co-cultured for 6 days at an E: T = 0.3:1 ratio, and the proliferation of tumor cells was observed. In both tumor cell lines, HCC1954 and SKOV3, the fourth-generation HER2 CAR-NK cells secreting IL-15 showed excellent cytotoxicity by inhibiting the proliferation of tumor cell lines, whereas the third-generation HER2 CAR-NK cells and HER2 CAR(t)-NK cells showed relatively low cytotoxicity (Fig. 3). The third-generation HER2 CAR-NK may not have effectively suppressed tumor cell formation due to the absence of additional cytokines such as IL-2, and the low cytotoxic effect observed in HER2 CAR(t)-NK cells may have been due to the lack of a signaling domain.

[0122]

[0123] 3-2) Evaluation of IFN-γ secretion capacity

[0124] When measuring the amount of IFN-γ secreted by NK cells, which is one of the functional cytokines secreted when they come into contact with target tumor cells, we observed that 3rd generation HER2 CAR-NK cells and HER2 CAR(t)-NK cells hardly secreted IFN-γ, whereas 4th generation CAR-NK cells secreted IFN-γ at very high levels (Fig. 4). Through this, it was confirmed that, unlike 3rd generation CAR-NK cells that did not survive and proliferate smoothly, 4th generation CAR-NK cells exhibited a synergistic anti-tumor effect due to the co-expression of IL-15 and the chimeric antigen receptor of the present invention that includes OX40L as a signaling domain.

[0125]

[0126] Example 4: Culturing NK cells and freezing cells at different culture time points

[0127] 4-1) Cell thawing

[0128] Frozen cells were rapidly thawed in a preheated 37°C water bath. When more than 90% thawed, the cells were transferred to a 50 mL tube on a biological safety cabinet, and a 10-fold (v / v) volume of ACD buffer was slowly added. The cells were then centrifuged at 1,200 rpm and 4°C for 10 minutes, the supernatant was completely removed, and the cells were suspended in CellGro medium and the cell count was determined.

[0129]

[0130] 4-2) NK cell culture and transduction using lentiviral vectors

[0131] Day 0 of culture 1.0 x 10 6 / mL of NK cells and 2.5 x 10 6 / mL of supporting cells and CellGro medium were mixed in a 1:1:1 ratio and cultured in a CO2 incubator at 37℃. At this time, Cellgro medium supplemented with IL-2 (1,000 IU / mL), human plasma (2%), and OKT3 (10 μg / mL) in an amount corresponding to the total volume was used. On the 4th day of culture, CellGro mixed medium containing IL-2 (1,000 IU / mL) and human plasma (1%) was added in an amount equal to the total volume. On the 7th day of culture, all cells were harvested and the cell number was measured without any separate dilution, and 0.66 x 10 6 / mL or more, the cells were frozen. On the 7th day of culture, the frozen cells were thawed, the raw cells were suspended in CellGro medium, and the cell count was measured to be 1.0 x 10 6 Cells were cultured at a concentration of 1.0 x 10 / mL. On the 10th day of culture, 1.0 x 10 6 To treat 6.6 x 10 / mL of cells with 20 MOI of lentiviral vector 830 μL of lentiviral vector at TU / mL was treated with the mixture, and the composition of the mixture for lentiviral vector transduction is as shown in Table 3 below.

[0132] Composition of each solution for lentiviral vector transduction Mixture Solution Storage Capacity Final Concentration 1 Lentiviral Vector Not applicable 20 MOI / 1×10 6 cellsProtransduzin RUODMSO10 mg / mL10μg / mL2IL-21100μg / mL20 ng / mLhuman plasmaN / A1%IL-22500000 IU / mL1,000 IU / mLGlutamine200 mM2%CellGro mediumN / A1

[0133] After preparing Mixture 1 and 2 respectively, they were slowly added to the culture vessel. For CBNK that was not transduced with lentiviral vector, 1 mL of CellGro medium was added with mixed medium (hereinafter referred to as CellGro mixed medium) containing human plasma (1%) and IL-2 (1,000 IU), and then cultured in a CO2 incubator at 37°C. On the 11th day of culture, the same volume of CellGro mixed medium as on the 10th day of culture for 6-well was added and IL-21 was added at a concentration of 20 ng / mL. On the 13th day of culture, the cells were harvested and 1 x 10 were added to the CellGro mixed medium without any separate dilution. 6 / mL. On the 16th day of culture, CD5-positive cells were isolated to obtain NK cells expressing CD5 CAR. To do this, all NK cells were collected, centrifuged at 1200 rpm and 4°C for 5 minutes, the supernatant was removed, and the cell number was measured after suspending in MACS buffer, and 1.0 x 10 7 / mL of MACS buffer was added. Then, biotin-tagged recombinant human CD5 protein (His & AVI tag) (250 μg / mL) was added at 1 μL / 10 6After adding the cells and mixing well, the reaction was carried out at 4℃ for 30 minutes. 10 times the volume of MACS buffer was added as the first reaction volume, centrifuged at 340g and 4℃ for 10 minutes, and the supernatant was removed. 1.0 x 10 8 After suspension with MACS buffer to make / mL, anti-biotin beads (Miltenyi Biotec, 130-092-357) were added at 37.5μL / 40 x 10 6 cells and reacted at 4°C for 15 minutes. 10 times the volume of MACS buffer was added, centrifuged at 340 g for 10 minutes at 4°C, and the supernatant was removed. 1.0 x 10 8 After adding MACS buffer to cells / 500 μL, the cells were well lysed by pipetting several times. QuadroMACS TM An LS column (Miltenyi Biotec) was mounted on a separator (Miltenyi Biotec) and activated by flowing 3 mL of MACS buffer. After thoroughly dissolving the cells that had reacted with the beads by pipetting, 500 μL was added to each column and the cell suspension was allowed to settle completely. To wash the column, 3 mL of MACS buffer was flowed through the column, washing it a total of three times. The column was placed on a QuadroMACS TM After separation in the separator, 5 mL of MACS buffer was added and the CD5 CAR positive cells were recovered by plunger. The separated cells were centrifuged and 1 x 10 6 / mL of CellGro mixed medium was added, and re-stimulation using support cells was performed in the same manner as on day 0 of culture, and then cultured in a CO2 incubator at 37°C. On day 19 of culture, the same volume of CellGro mixed medium as on day 16 of culture was added. On day 21 of culture, cells were harvested, the number of cells was measured without separate dilution, and CellGro mixed medium was added to obtain 1 x 10 6 / mL, and then add CellGro mixed medium until 28 to 30 days of culture to adjust to 1 x 10 6 / mL concentration. After harvesting all NK cells on day 28 to 30 of culture, the cells were frozen. Hereinafter, cells frozen after culture on day 28 to 30 are designated as “MCB.” The remaining cells were cultured at 1.0 x 10 6 After adding CellGro medium to reach / mL, re-stimulation using support cells was performed as on the 16th day of culture, and the cells were cultured in a CO2 incubator at 37°C. After that, CellGro mixed medium was added for 14 days to reach 1 x 10 6 / mL concentration. After harvesting all NK cells on days 42 to 44 of culture, the cells were frozen, and the frozen cells were named “DP.”

[0134] 4-3) Cell freezing

[0135] After centrifugation, suspend the cells in PBS and mix with freezing medium mixture in a 1:1 ratio, 100 x 10 per freezing container. 6 / mL and the cells were frozen using an automated cell freezer (CRF).

[0136]

[0137] Example 5: Characterization of CD5 CAR-transduced NK cells

[0138] 5-1) Confirmation of CD5 CAR expression

[0139] 1 - 5 x 10 5The cells were harvested, centrifuged, the supernatant removed, and suspended in 2 mL of FACS buffer containing 2% FBS. The cells were centrifuged to remove the supernatant, and 100 μL of FACS buffer and 1 μL of biotin-tagged recombinant human CD5 protein (His & AVI tag) (250 μg / mL) were added and reacted at 4°C for 30 minutes in a dark environment. After that, 2 mL of FACS buffer was added, centrifuged, and the supernatant was removed. For secondary staining, 100 μL of cell buffer was added to the washed NK cells, and the antibodies to be used for analysis were added and reacted at 4°C for 30 minutes in a dark environment.

[0140] Antibodies for CD5 CAR-NK expression confirmation Antibody volume Streptavidin-PE 0.5 μL Anti-human CD56 APC5 μL Anti-human CD3-PE-Cy71 μL 7-AAD5 μL LFACS buffer Up to 100 μL Total volume 100 μL

[0141] After adding 2 mL of FACS buffer, centrifugation was performed, the supernatant was removed, 200 μL of BD cytofix solution was added, and the stained cells were analyzed using an LSRfortessa device. The raw data were analyzed using the Flowjo program, and the gating was performed in the following order: “singlet → lymphocytes → living cells (7-AAD-) → NK cells (CD56+, CD3-) → CD5 CAR expression.” After thawing, the CD5 CAR expression rate of MCB was 96.46±2.00 (mean±standard deviation), and that of DP was 93.68±2.23 (mean±standard deviation). More than 90% of cells in both MCB and DP expressed CD5 CAR (Fig. 6). The statistical significance of the values ​​was confirmed through a two-tailed t-test (Table 5, *p<0.05, **p<0.01, ***<0.001, ns: no significance). The above results showed that CD5 CAR expression was well maintained even when the culture period was extended, and it was confirmed that CD5 CAR expression did not decrease rapidly even when frozen cells were thawed.

[0142] CAR expression rate of MCB and DP CAR expression % MFCBNK (MCB) average 0.19 233.65 STD 0.08 101.10 CD5 CAR-NK (MCB) average 96.46 13437.68 STD 2.00 482.37 p-value of CBNK (MCB) vs CD5 CAR-NK (MCB) 0.000 10.000 4 CBNK (DP) average 0.26 245.49 STD 0.14 136.91 CD5 CAR-NK (DP) average 93.68 10443.52 STD 2.23 2875.77 p-value of CBNK (DP) vs CD5 CAR-NK (DP) 0.000 20.02 32 p-value of CD5 CAR-NK (MCB) vs CD5 CAR-NK (DP) 0.0093 ns

[0143]

[0144] 5-2) Phenotype confirmation of CD5 CAR-transduced NK cells

[0145] NK cells 1.0-2.5 x 10 6 After suspension in FACS buffer at a concentration of 10 / mL, 100 μL was dispensed onto the plate containing the antibody mixture. Pipetting was performed several times to ensure good mixing of cells and antibodies. The composition of the antibody mixture is as shown in Table 6 below, and the PE antibody corresponding to each phenotype was added.

[0146] Composition of antibody mixture for phenotypic staining PE_Cy7PEAPCPerCP_Cy5.5Total staining volume (μL)PE_Cy7Volume (μL)PEVolume (μL)APCVolume (μL)PerCP_Cy5.5 Volume (μL)1CD31CD165CD5657-AAD5162NKG2A1123NKG2C1124NKG2D5165NKp301126NKp445167NKp465168CXCR35169DNAM-151610CD2551611 CD5711212CD62L11213CD6951614PD-111215TIGIT11216LAG311217TIM31121 8KLRG-111219(FMO1)mIgG151620(FMO2)mIgG2a516 subtypemIgG11mIgG15mIgG1516

[0147]

[0148] After reacting for 30 minutes at 4℃, 100μL of FACS buffer was added and mixed by pipetting, centrifuged (2000 rpm, 3 minutes, 4℃), and 200μL of BD cytofix solution was dispensed into each well. After performing flow cytometry using LSRfortessa equipment, the results were analyzed. NK cells were gated in the order of singlets → lymphocytes → living cells (7-AAD-) → NK cells (CD56+, CD3-), and the expression of each marker was calculated based on the subtype antibody. To analyze the characteristics of NK cells, the expression of 18 types of surface markers was analyzed by flow cytometry, and the MCB and DP of CD5 CAR-NK were compared with the MCB and DP of CBNK. As a result, the expression of each surface marker in CD5 CAR-NK did not differ significantly compared to CBNK, and there was no significant difference between the MCB and DP (Fig. 7, Table 7).

[0149]

[0150]

[0151] Example 6: In vitro efficacy evaluation of CD5 CAR-transduced cells

[0152] 6-1) Production and culture of tumor cell lines

[0153] Frozen K562, NALM6, CCRF-CEM, RPMI-8402_Luc, NALM6-NucLight, CCRF-CEM-NucLight, and RPMI-8402-NucLight cells were rapidly thawed in a 37°C water bath, diluted in 10 mL of culture medium, centrifuged to remove the supernatant, and added 1 mL of medium to measure the cell count. 1-2 x 10 6 The cells were placed in T75 flasks and cultured in a CO2 incubator for 2–3 days. To produce NucLight-labeled tumor cell lines, 8 μg / mL polybrene (Santa Cruz, CA, USA) was used to incubate the cell lines with Incucyte. ®Cells were transduced with NuclightRed lentivirus (Sartorius, Göttingen, Germany), and 4 days later, treated with puromycin (Gibco, USA) at concentrations of 0.5, 1, 1.5, and 2 μg / mL. After 7 days of puromycin treatment, the lowest concentration that resulted in 100% tumor cell death was selected, and only cells expressing red fluorescent protein were selected and cultured.

[0154]

[0155] 6-2) CD5 expression in tumor cells

[0156] Tumor cells were harvested and cultured at 1 - 5 x 10 5 Cells were transferred to a FACS tube. After centrifugation, 100 μL of FACS buffer was added and 1 μL of anti-human CD5 PE was mixed, and the mixture was incubated at 4℃ for 30 minutes in a dark place. After adding 1 mL of FACS buffer and centrifuging, the supernatant was discarded, and 200 μL of BD cytofix solution was added and mixed, and then FACS analysis was performed. As a result of the analysis, the gray shade shows the subtype control, the blue solid line shows the result of staining with anti-human CD5 antibody, and the number shows the expression rate (%) compared to the subtype control. While K562, NALM6, and NALM6-Nuclight barely expressed CD5, CCRF-CEM, CCRF-CEM-Nuclight, RPMI-8402_Luc, RPMI-8402-Nuclight, and Jurkat-Nuclight showed high expression of CD5 (Fig. 8).

[0157]

[0158] 6-3) Confirmation of CD107a and cytokine expression in CD5 CAR-transduced cells

[0159] NK cells and target tumor cell lines were each cultured at 2.5 x 10 in RPMI-1640 + 10% FBS (hereinafter referred to as assay medium). 6 / mL. To confirm whether it shows CD5-specific cell activity, CCRF-CEM and RPMI-8402_Luc were used as CD5-positive tumor cell lines, and NALM-6 was used as CD5-negative tumor cell line. Golgistop (1.3 μ / mL) and Golgiplug (2 μ / mL) were added and mixed to prevent cytokines produced in NK cells from being secreted. APC anti-human CD107a antibody (1 μL) was dispensed into the (-) well and target well in a 96-well round-bottom plate. In the (-) well of the plate where the antibody was dispensed, 100 μL of assay medium and 100 μL of NK cells were added to confirm the cytokine expression of the NK cells themselves, and 100 μL each of NK cells and the target tumor cell line were added together to the target well. A 96-well plate was wrapped in foil to block light and co-cultured for 4 hours in a 37°C CO2 incubator. After centrifugation (2000 rpm, 3 minutes, 4°C), the supernatant was removed, 200 μL FACS buffer was added, mixed, centrifuged, and the supernatant was removed. For cell surface staining, anti-human CD3 PerCP-Cy5.5 (1 μL), anti-human CD56-APC-e780 (1 μL), and 7-AAD (4 μL) were added to 100 μL FACS buffer per well and incubated at 4°C for 30 minutes. After adding 100 μL FACS buffer and centrifuging twice, the supernatant was removed, 200 μL fixation / permeabilization solution was added, and incubated at 4°C for 30 minutes. After centrifugation, the supernatant was removed, 200 μL 1 x Perm wash buffer was added, and centrifugation was performed. 100 μL 1 x Perm wash buffer was added per well, followed by addition of anti-human IFN-η FITC (1 μL) and anti-human TNF-α PE-Cy7 (1 μL) and incubation at 4°C for 30 minutes. After adding 100 μL 1 x Perm wash buffer, centrifugation was performed, the supernatant was removed, and 200 μL 1 x Perm wash buffer was added and centrifugation was performed.The supernatant was removed, 200 μL of BD cytofix was added, and the results were measured using an LSRFortessa FACS device and analyzed using the FlowJo analysis program. As a result, the expression of CD107a and cytokines (IFN-γη, TNF-α) for the K562 cell line, which is used when evaluating the activity of NK cells, showed high expression without much difference in CBNK and CD5 CAR-NK, and when co-cultured with the positive cell lines CCRF-CEM and RPMI-8402_Luc cell lines, the expression was more than twice as high in the CD5 CAR-NK group compared to CBNK, whereas the negative cell line NALM-6 showed a similar expression at a low level, confirming that cytokines are expressed specifically for CD5 (Fig. 9). The results of measuring the CD107a expression and two cytokines of three donors were statistically significant using a two-tailed t-test and are presented as the mean ± standard deviation in Table 8 (Fig. 9, *p<0.05, **p<0.01, ns: no significance). Compared to CBNK, CD5 CAR-NK showed a high CD107a expression and increased cytokine expression specifically for CD5, and there was no statistical significance between MCB and DP.

[0160] Mean expression values ​​of CD107α, IFN-η, and TNF-α (n=3) CD107αw / o target K562NALM6CCRF-CEMRPMI-8402_ Luc CBNK (MCB) Average 5.59 55.57 10.26 18.19 7.87 STD 8.48 14.85 11.58 8.79 7.99 CD5 CAR-NK (MCB) Average 7.97 48.5 59.15 45.37 30.6 STD 7.68 3.14 7.0 5 7.17 13.82 p-value of CBNK (MCB) vs CD5 CAR-NK (MCB) nsnsns 0.01 49 0.06 43 CBNK (DP) Average 4.14 46.69 7.96 19.8 25.72 STD 5.44 5.19 3.23 3.02 4.07 CD5 CAR-NK (DP) Average 7.56 47.5 19.87 43.15 24.4 STD 9.5 36.79 4.4 17.19 8.56 p-value of CBNK (DP) vs CD5 CAR-NK (DP) nsnsns 0.04 29 0.02 5 1 p-value of CD5 CAR-NK (MCB) vs CD5 CAR-NK (DP) nsnsns 0.05 7 3 0.49 14 IFN-γ w / o target K562 NALM6 CCRF-CEMRPMI-8402_ Luc CBNK (MCB) Average 3.3 56.5 14.6 69.89 3.76 STD 2.8 36.6 2.37 0.2 0.98 CD5 CAR-NK (MCB) Average 7.6 5 0.9 7.8 5 4.7 4. ... p-value of vsCD5CAR-NK(DP)nsnsns0.00640.0072p-value of vsCD5CAR-NK(MCB) vsCD5CAR-NK(DP)nsnsns0.49590.3298TNF-αw / o targetK562NALM6CCRF-CEMRPMI-8402_ LucCBNK (MCB)average3.4944.497.5410.275.45STD4.7818.618.036.535.91CD5 CAR-NK (MCB) average 4.3835.725.9441.3337.24STD 3.93.094.53.765.18p-value of CBNK (MCB) vs CD5 CAR-NK (MCB)nsnsns0.00420.0024CBNK (DP) average 3.8241.666.8312.945.14STD 5.1543.542.224.09CD5 CAR-NK (DP) average 3.8342.287.5945.4735.34STD 4.475.33.610.462.81p-value of CBNK (DP) vs CD5 CAR-NK (DP)nsnsns0.00220.0018CD5 CAR-NK (MCB) p-value of vsCD5CAR-NK(DP)nsnsns0.20010.4893.

[0161]

[0162] 6-4) Evaluation of tumor cell killing ability of CD5 CAR-transduced cells

[0163] NK cells (CBNK, CD5 CAR-NK) were harvested and centrifuged at room temperature, 1200 rpm for 5 minutes. The supernatant was removed, suspended in 1 mL assay medium, and the cell number was measured. Transduced cells were added to a 5 mL FACS tube by suspending them in assay medium at the ratio of E (NK cells):T (target cells). NK cells were suspended in a 10:1 ratio at 1 x 10 5 cells / 100μL, 3:1 ratio is 3 x 10 4 cells / 100μL, 1:1 ratio is 1 x 10 4 cells / 100μL, 0.3:1 ratio is 3 x 10 3 It was prepared to be cells / 100μL.

[0164] 1 x 10 of target cell lines were seeded in a 96-well round-bottom plate. 4 cells / well(1 x 10 5cells / mL, 100 μL) and NK cells were added at 100 μL each according to the E:T ratio. To correct the fluorescence value for Calcein-AM released by itself from target cells stained with Calcein-AM, 100 μL of target cells and 100 μL of assay medium were added, and the measured value was used as the minimum release value. To measure the maximum Calcein-AM fluorescence value released from target cells, 100 μL of target cells and 100 μL of 2% Triton X-100 were added until all cells were lysed, and the measured fluorescence value was used as the maximum release value. To correct for the lowering of fluorescence value due to Triton X-100, 200 μL of assay medium was added to MM wells, and 100 μL of assay medium and 100 μL of 2% Triton X-100 were added to MT wells. After culturing for 4 hours in a 37°C incubator under light, the cells were centrifuged at 4°C and 2000 rpm for 3 minutes. 100 μL of the supernatant was transferred to a black 96-well flat-bottom plate, and the fluorescence value was measured using a fluorometer under conditions of 458 nm / 535 nm, 0.1 s, and the cell killing activity was calculated according to the formula in Table 9.

[0165] How to calculate NK cell killing power How to calculate NK cell killing power MM well average fluorescence value - MT well average fluorescence value = Specific lysis ratio A% = [(sample well average fluorescence value - minimum release well average fluorescence value) / (maximum release well average fluorescence value + A) - minimum release well average fluorescence value] x 100

[0166] The cell killing ability of CBNK (MCB), CD5 CAR-NK (MCB), CBNK (DP), and CD5 CAR-NK (DP) against four types of target cells from three donors (2024P, 2044P, 605463P) is shown in Fig. 7, and the cell killing ability values ​​(%) for each are summarized in Table 10. As shown in Fig. 11 and Table 10, the tumor killing ability of CD5 CAR-NK cells against the CD5-positive cell lines CCRF-CEM and RPMI-8402-Luciferase cells was higher than that of CBNK, and the difference between CD5 CAR-NK (MCB) and CD5 CAR-NK (DP) was not significant (two-tailed t-test *p<0.05, **p<0.01, ***<0.001, ns: not significant).

[0167] Cell killing activity (%) in 3 donors (2024P, 2044P, 605463P) K562 10:13:11:10.3:1 CBNK (MCB) Average 82.65 74.0 245.16 18.80 STD 2.96 4.8 16.25 6.08 CD5 CAR-NK (MCB) Average 82.5 371.45 39.17 14.13 STD 7.87 4.24 4.0 85.14 p-value of CBNK (MCB) vs CD5 CAR-NK (MCB) nsnsnsns CBNK (DP) Average 82.13 57.72 25.4 38.28 STD 6.74 3.8 34.27 2.65 CD5 CAR-NK (DP) average 92.76 65.25 30.27 8.26 STD 6.6 17.4 08.3 25.59 p-value of CBNK (DP) vs CD5 CAR-NK (DP) nsnsnsns p-value of CD5 CAR-NK (MCB) vs CD5 CAR-NK (DP) nsnsnsns 0.0264 NALM 6 10:13:11:10.3:1 CBNK (MCB) average 15.6 09.4 85.3 13.54 STD 4.27 4.4 4.25 2.93 CD5 CAR-NK (MCB) average 6.7 5 2.9 10.43 -0.75 STD 3.1 4 3.0 4 3.8 9 2.95 CBNK (MCB) vs CD5 CAR-NK (MCB) p-value 0.02860.02260.02420.0291CBNK (DP) average 6.963.113.806.78STD 7.683.662.792.59CD5 CAR-NK (DP) average 13.513.451.753.95STD 14.695.432.192.60p-value of CBNK (DP) vs CD5CAR-NK (DP)nsns0.0450.0017p-value of CD5 CAR-NK (MCB) vs CD5 CAR-NK (DP)nsnsnsnsCCRF-CEM10:13:11:10.3:1CBNK (MCB) average 29.6818.5610.864.83STD 7.084.963.051.64CD5 CAR-NK(MCB)Average59.0448.7629.6611.09STD2.832.593.542.43CBNK(MCB) vs CD5CAR-NK(MCB)p-value0.03450.01820.0378nsCBNK (DP)Average24.9111.535.162.98STD7.864.650.740.74CD5 CAR-NK (DP) average 74.20 50.30 20.90 6.86 STD 7.06 7.02 4.33 3.68 p-value of CBNK (DP) vs CD5 CAR-NK (DP) 0.000 20.006 30.02 37 ns p-value of CD5 CAR-NK (MCB) vs CD5 CAR-NK (DP) ns 0.04 37 ns RPMI-8402 Luciferase 10:13:11:10.3:1 CBNK (MCB) average 15.2 78.13 5.17 3.52 STD 5.29 3.71 2.6 64.91 CD5 CAR-NK (MCB) average 61.76 36.60 13.9 7 3.29 STD 2.3 73.78 2.7 34.45 CBNK (MCB) p-value of vs CD5 CAR-NK(MCB)0.00820.00440.0051nsCBNK (DP)average6.442.262.094.90STD0.772.603.483.61CD5 CAR-NK(DP)average60.1227.429.284.86STD11.073.842.823.38p-value of vs CD5 CAR-NK(DP)0.01290.01440.0028nsCD5 CAR-NK(MCB) vs CD5 CAR-NK(DP)ns0.0025nsns.

[0168]

[0169] 6-5) Confirmation of IFN-γ secretion ability of CD5 CAR transduced cells

[0170] Dilute target cells in assay medium and add 1 x 10 5 / mL and dilute NK cells in assay medium to 3 x 10 5 After preparing at a concentration of / mL, 100 μL was dispensed into each 96-well round-bottom plate and co-cultured at an E:T = 3:1 ratio. After culturing for 24 hours in a 37°C, 5% CO2 incubator, the supernatant was collected and stored at -20°C.

[0171] ELISA was performed for IFN-γ quantification. The day before the experiment, the '200 x capture antibody' was diluted in '1x coating buffer A', 100 μL was added to a 96-well plate, and incubated at 2-8°C for 16-18 hours. On the day of the experiment, the plate was washed four times using washing buffer, and 200 μL of '1 x assay diluent A' was added to each well to inhibit nonspecific binding. The plate was sealed and left on a plate shaker for 1 hour. Standards were prepared by serially diluting 'interferon gamma standard stock solution' in '1x assay diluent A' (500, 250, 125, 62.5, 31.3, 15.6, 7.8, 0 pg / mL). After that, the supernatant stored at -20℃ was thawed and diluted 1 / 10 in '1 x Assay Diluent A' to prepare samples. 100 μL of the standard and the diluted sample were dispensed into each well, the plate was sealed, and incubated on a plate shaker at room temperature for 2 hours. The plate was washed 4 times using wash buffer. 100 μL of '1 x Detection Antibody' was added to each well, the plate was sealed, and incubated on a plate shaker at room temperature for 1 hour. The plate was washed 4 times using wash buffer. 100 μL of '1 x Avidin-HRP' was added to each well, the plate was sealed, and incubated on a plate shaker at room temperature for 30 minutes. The plate was washed 5 times using wash buffer, and 100 μL of 'TMB Substrate' was added to each well, and incubated under light for 20 minutes at room temperature. The reaction was terminated by adding 100 μL of 'Stop solution', and the absorbance was measured at a wavelength of 450 nm using a spectrophotometer. As a result, in the CD5-negative cell lines K562 and NALM6, there was a difference in IFN-γ secretion between CBNK (MCB, DP) and CD5 CAR-NK (MCB, DP) of three donors (2024P, 2044P, 605463P), but there was no significant difference when the results of all donors were analyzed together.In the CD5-positive cell lines CCRF-CEM and RPMI-8402-Luciferase, CBNK (MCB, DP) from donor 2024P secreted 40-60 pg / mL of IFN-γ, and CD5 CAR-NK (MCB, DP) from donor 2024P secreted 350-550 pg / mL of IFN-γ, which was about 8-9 times higher than that of CBNK. In the donor 2044P, CBNK (MCB, DP) from donor 2044P secreted 45-55 pg / mL of IFN-γ, and CD5 CAR-NK from donor 2044P secreted 250-350 pg / mL of IFN-γ, which was about 5-6 times higher than that of CBNK. In donor 605463P, CBNK (MCB, DP) secreted 70-120 pg / mL of IFN-γ, and CD5 CAR-NK (MCB, DP) secreted 600-1300 pg / mL, indicating that CD5 CAR-NK secreted 8-10 times more IFN-γ than CBNK. Overall, all three donors showed enhanced IFN-γ secretion ability in CD5 CAR-NK specifically for CD5-positive cell lines, and the results were statistically significant (Fig. 12, *p<0.05, **p<0.01, ***<0.001, ****<0.0001, ns: not significant). There was no statistical significance between CD5 CAR-NK (MCB) and CD5 CAR-NK (DP).

[0172] IFN-γ secretion capacity (pg / mL) for 3 donors IFN-gK562NALM6CCRF-CEMRPMI-8402_LucCBNK (MCB) Average 357.54 31.32 45.56 37.56 STD 365.59 21.42 37.40 27.52 CD5 CAR-NK (MCB) Average 386.74 76.47 646.38 556.69 STD 146.29 30.05 285.06 156.63 p-value of CBNK (MCB) vs CD5 CAR-NK (MCB) ns 0.002 1<0.0001<0.0001 CBNK (DP) Average 304.1237.8454.6745.59 STD 228.4425.6946.7237.87 CD5 CAR-NK (DP) Average 303.8859.91707.42581.36 STD 142.759.07443.92194.58 p-value of CD5 CAR-NK (DP) vs CD5 CAR-NK (DP) ns 0.02720.0005<0.0001 p-value of CD5 CAR-NK (MCB) vs CD5 CAR-NK (DP) ns ns ns

[0173]

[0174] 6-6) Confirmation of IL-15 secretion ability of CD5 CAR transduced cells

[0175] Dilute target cells and NK cells in assay medium, target cells are 2 x 10 6 / mL, NK cells are 6 x 10 6 / mL concentration was prepared. 100 μL each was dispensed into a 96-well round-bottom plate and co-cultured at a ratio of E:T = 1:3 in a 37°C, 5% CO2 incubator for 24 hours. The supernatant was obtained and stored at -20°C.

[0176] ELISA analysis was performed using the IL-15 ELISA kit. Microplate strips were placed in a plate mold, and 100 μL of assay dilution RD1-19 was dispensed into each well. 50 μL of the IL-15 standard and the stored supernatant were dispensed into the plate, and the plate was incubated for 3 hours at room temperature on a shaker. The plate was washed four times with wash buffer. 200 μL of the IL-15 conjugate was added to each well, and the plate was incubated for 45 minutes at room temperature on a shaker. After washing the plate four times with wash buffer, 200 μL of the 'Substrate solution' was added, and the plate was incubated for 30 minutes at room temperature, protected from light. The reaction was terminated by adding 50 μL of the 'Stop solution', and the absorbance was measured at a wavelength of 450 nm. As a result, as shown in Fig. 13 and Table 12 below, under the condition of culturing only NK cells without target cells (effector only), IL-15 was secreted at the level of 4-6 pg / mL for CBNK (MCB, DP) and 5-17 pg / mL for CD5 CAR-NK (MCB, DP) from three donors. In the CD5-negative cell lines K562 and NALM6, IL-15 was secreted at a level similar to that of the group in which only NK cells were cultured (effector only) from CBNK (MCB, DP) and CD5 CAR-NK (MCB, DP) from three donors. For the CD5-positive cell lines CCRF-CEM and RPMI-8402-Luciferase, CBNK (MCB, DP) secreted IL-15 at levels similar to those of CD5-negative cell lines. In CD5 CAR-NK (MCB, DP), IL-15 secretion increased to 25-60 pg / mL for donor 2024P, 8-13 pg / mL for donor 2044P, and 20-50 pg / mL for donor 605463P, showing statistically significant results in both MCB and DP compared to CBNK. There was no statistical significance between CD5 CAR-NK (MCB) and CD5 CAR-NK (DP) (Fig. 13, *p<0.05, **p<0.01, ns: no significance).

[0177] IL-15 secretion amount in MCB and DP (pg / mL) IL-15Effector only K562NALM6CCRF-CEMRPMI-8402_LucCBNK (MCB) average 4.97 5.88 4.98 5.06 5.81 STD 0.24 0.59 0.24 0.28 0.29 CD5 CAR-NK (MCB) average 12.2 111.80 8.4 139.97 20.95 STD 5.00 3.78 2.23 21.81 8.32 p-value of CBNK (MCB) vs CD5 CAR-NK (MCB) 0.005 30.00 36 0.00 38 0.00 29 0.00 12 CBNK (DP) Average 4.97 4.99 4.95 4.86 5.58 STD 0.41 0.16 0.12 0.25 0.20 CD5 CAR-NK (DP) Average 7.65 8.55 6.59 19.85 13.27 STD 1.86 2.89 1.58 11.39 5.98 p-value of CBNK (DP) vs CD5 CAR-NK (DP) 0.006 30.01 310.03 020.00 9 20.01 03 p-value of CD5 CAR-NK (MCB) vs CD5 CAR-NK (DP) nsnsnsnsns

[0178]

[0179] 6-7) Long-term tumor cell line killing ability analysis test of NK cells introduced with CD5 CAR gene

[0180] To evaluate the long-term tumor cell killing ability of NK cells introduced with the CD5 CAR gene, tumor cell lines expressing red fluorescent protein were co-cultured with CD5 CAR cells from three donors for 96 hours to determine the tumor cell line killing ability. NALM6, a CD5-negative B cell-derived cancer cell line, and CCRF-CEM and RPMI-8402, CD5-positive acute T lymphoblastic leukemia cell lines, were used in the experiment. Tumor cells were seeded at a density of 1 x 10 using assay medium (RPMI 1640 containing 10% FBS (Gibco, 11875093)). 5cells / mL. To form tumor cell lines into spheroids, 100 μL per well was added to a 96-well ULA (ultra-low attachment) plate (Corning) and centrifuged at 125 g, 4 °C, for 10 minutes. NK cells co-cultured with NALM6 and RPMI-8402 were cultured at a concentration of 1 x 10 5 cells / mL (E:T ratio = 1:1) and NK cells co-cultured with CCRF-CEM were 0.3 x 10 5 After suspending the cells in the assay medium at a concentration of 10 cells / mL (E:T ratio = 0.3:1), 100 μL was added to each well containing tumor cells. For the tumor cell-only control group, 100 μL of the assay medium was added with 100 μL of tumor cells instead of NK cells. The plate was placed in an Incucyte S3 instrument (Sartorius) and co-cultured for 96 hours, and the red fluorescence intensity (All Brightfield Object Total Red Integrated Intensity, RCU x μm) within the tumor cell spheroids was measured. 2 / Image) were analyzed using Oncocyte Spheroid Analysis Software (v2019B). The graph shows the red fluorescence intensity of the co-cultured wells at each time point normalized to the red fluorescence intensity of the well containing only tumor cells. As shown in Figure 10, the tumor killing ability of NK cells isolated from three donors against CD5-negative NALM6 cells was similar to that of CBNK cells. For the CD5-positive tumor cells CCRF-CEM, CD5 CAR-NK cells (MCB, DP) consistently inhibited tumor cell growth compared to CBNK cells (MCB, DP), and the tumor cell proliferation inhibition ability of the MCB and DP of donor 1 was similar. On the other hand, in donors 2 and 3, the tumor cell killing ability of CD5 CAR-NK cells (MCB) was higher than that of CD5 CAR-NK cells (DP) when co-cultured with CCRF-CEM. For the CD5-positive tumor cells RPMI-8402, the tumor cell killing ability of CD5 CAR-NK cells (MCB) was higher than that of CD5 CAR-NK cells (DP) for two donors (donors 1 and 3), but the CD5 CAR-NK cells (DP) from donor 2 did not show tumor killing ability (Fig. 14), and the significance was confirmed through a two-tailed t-test (*p<0.05, **p<0.01, ***<0.001, ns: no significance). In conclusion, the long-term tumor cell killing ability of CD5 CAR NK cells against CD5-positive tumor cells was confirmed, and CD5 CAR-NK (MCB) cells showed higher killing ability than CD5 CAR-NK (DP) cells (Table 13).

[0181] Long-term tumor cell killing ability of CD5 CAR NK cells NALM-6 (0.3:1) CCRF-CEM (0.3:1) RPMI-8402 (1:1) Target only Average 100 100 100 STD 000 CBNK (MCB) Average 102.00 85.88 108.41 STD 7.7 15.47 5.44 p-value of CBNK (MCB) ns ns CAR-NK (MCB) Average 109.92 12.82 54.08 STD 12.05 6.5 123.27 p-value of CAR-NK (MCB) ns < 0.000 10.006 CBNK (DP) Average 108.50 88.07 106.36 STD 5.3 35.5 22.23 p-value of CBNK (DP) ns ns CAR-NK (DP) Average 114.07 30.45 79.49 STD 14.77 22.56 11.52 CAR-NK (DP) p-value 0.0157 <0.0001 ns

[0182]

[0183] Example 7: Evaluation of in vivo efficacy of CD5 CAR-transduced cells

[0184] 7-1) Tumor cell culture and freezing

[0185] RPMI-8402-Luc cell line, which was produced by inserting CML-Luc lentiviral vector into RPMI-8402, a human T-cell acute lymphoblastic leukemia cancer cell line, was cultured. The cancer cell line culture medium used was IMDM medium (ATCC) containing 10% (v / v) fetal bovine serum (FBS) (Gibco) and 2.0 μg / mL puromycin (Gibco), and the cell concentration when culturing the cancer cell line was 1 x 10 5 The cells were cultured in a culture vessel of an appropriate volume by adjusting the concentration to cells / mL. For freezing of cancer cell lines, a cancer cell line culture medium containing 20% ​​DMSO (Avantor) was used and stored in an ultra-low temperature freezer using Mr. Frosty (freezing vessel) (Thermo Fisher) for less than a week, and then transferred to an ultra-low temperature liquid nitrogen tank for storage.

[0186]

[0187] 7-2) Tumor cell line xenotransplantation and NK cell administration

[0188] Specific pathogen free (SPF) NOD.Cg-Prkdc for laboratory animals scid IL2γg tm1Sug / JicKoat (hereinafter referred to as NOG) mice (supplied by Saeron Bio (manufactured by: Coretech Co., Ltd.)) were used as 6-week-old females. Cancer cells to be used for mouse tumor transplantation were prepared by thawing frozen cell lines and subculturing them once every 3-4 days. On the day of tumor transplantation into the mice, all cancer cells were collected, centrifuged, and resuspended using PBS. The administration conditions of tumor cells and NK cells were divided into ① comparison according to the number of administrations and administration doses (MCB), and ② comparison according to culture conditions (MCB, DP) and conducted experiments.

[0189] ① In case of comparison according to the number of administrations and dosage, 5 x 10 tumor cell lines 6 A cell suspension was prepared at a concentration of 1 × 10 cells / mL. 0.2 mL of the prepared cell suspension was injected into the tail vein of each mouse in each experimental group to obtain a concentration of 1 × 10 6 Cancer cells were transplanted into the mice at a rate of cells / head. Three days after transplantation, CBNK (MCB) and CD5 CAR-NK (MCB) cells were administered three times: (A) single administration; (B) three times at two-week intervals; and (C) three times at once-weekly intervals (Table 14). Frozen NK cells were thawed, resuspended in freezing medium to a concentration appropriate for the experimental conditions, and then injected into the tail vein of the mice at 0.2 mL each, either single or three times. For the three-time administration, NK cells were administered on days 3, 7, and 10 based on twice-weekly administration, and on days 3, 10, and 17 based on once-weekly administration. For the test group administered three times a week, 2 x 10 6 , 5 x 10 6 , 1 x 10 7The dose of CD5 CAR-NK (MCB) was divided into cells / head and administered. The experimental group was administered only PBS as a control group and 1 x 10 cancer cell lines 6 A tumor only experimental group was added, which administered only cells / heads, and each experimental group included 3 or 5 individuals.

[0190] ② In case of comparison according to culture period (MCB, DP), tumor cell lines were 1.5 x 10 7 A cell suspension was prepared at a concentration of 10 cells / mL. 0.2 mL of the prepared cell suspension was injected into the tail vein of each mouse in each experimental group, resulting in a total of 3 x 10 6 Cancer cells were transplanted at a rate of 1 x 10 cells / head. CBNK (MCB) and CD5 CAR-NK (MCB, DP) cells were injected at a single dose of 1 x 10 3 days after transplantation. 7 cells / head were administered (Table 15). As a control group, an experimental group was administered only PBS, and 3 x 10 cancer cell lines 6 A tumor only experimental group was added, which administered only cells / heads, and each experimental group included 3 or 5 individuals.

[0191] NK cell administration conditions (① Comparison by number of administrations and dosage) Group Administration substance Administration amount (cells / head) Administration interval Number of administrations Number of individuals Control group PBS N / AN / AN / A3 Tumor only N / AN / AN / A5 (A) CBNK (MCB) 1 x 10 7 1 x 10 5CD5 CAR-NK (MCB) 7 1 x 1 x 5(B)CBNK (MCB)1 x 10 7 5CD5 CAR-NK (MCB) 1 x 10 2 times a week 3 times a week 7 2x3x5(C)CBNK (MCB)1 x 10 per week 7 5CD5 CAR-NK (MCB) 1 x 10 once a week, 3 times a week 7 5CD5 CAR-NK (MCB) 5 x 10 3 times a week 6 5CD5 CAR-NK (MCB) 2 x 10 once a week, 3 times a week6 3 times a week5

[0192] NK cell administration conditions (② Comparison according to culture period (MCB, DP)) Group Administration substance Administration amount (cells / head) Administration interval Administration frequency Number of individuals Control group PBS N / AN / AN / A3 Tumor only N / AN / AN / A5 Experimental group CBNK (MCB) 1 x 10 7 1 x 10 CD5 CAR-NK (MCB) 3 times a week 7 7CD5 CAR-NK (DP) 1 x 10 once a week, 3 times a week 7 3 times a week7

[0193]

[0194] 7-3) Evaluation of CD5 CAR-NK cell efficacy according to administration frequency and dosage in mice

[0195] For all animals, general symptoms were measured twice a day (once on weekends and holidays) during the experimental period and body weight changes were measured three times a week, and then once a week starting on day 60 after cancer cell transplantation. Death was also observed, and the median survival time of all groups was calculated using GraphPad Prism to evaluate the survival rate. After intraperitoneal injection of 50 μL of 15 mg / mL D-luciferin (GOLDBIO) into each side of the abdomen of the mice, small animal bioimaging (Perkin Elmer, IVIS Spectrum Series) was performed under inhalation anesthesia with 2% isoflurane for 7 minutes. Images were taken once a week from the day of cancer cell transplantation for a total of 13 times (0, 7, 14, 21, 28, 35, 42, 49, 56, 70, 84, 102, and 112 days from the transplantation date). As a result, hindlimb paralysis symptoms were observed in all animals in the CBNK (MCB) administration group around 40 days regardless of the number of administrations, and all animals died within 2 weeks after the onset of symptoms. Compared to the tumor only group, death occurred at an earlier time point, resulting in a median survival time of 48 to 50 days (Table 16). In the CD5 CAR-NK (MCB) administration group, hindlimb paralysis symptoms were not observed in the single administration group, and hindlimb paralysis symptoms were observed only in some animals in the group administered three times at twice-weekly intervals and the group administered three times at once-weekly intervals. As a result of comparing the doses, more animals showed hindlimb paralysis symptoms when administered at a low dose. At the final observation time of 137 days, the median survival time in the CD5 CAR-NK (MCB) administration group was 129 days in the single administration group, >137 days in the group administered three times at twice-weekly intervals, and 5 x 10 in the group administered three times at once-weekly intervals. 6 , 1x10 7 cells / head in all experimental groups >137 days, 2 x 10 6The cells / head experimental group showed a survival extension effect of more than twice that of the tumor-only and CBNK (MCB) administration groups, which had a median survival period of approximately 50 days at 100 days (Table 16). In the group administered three times a week, a trend was confirmed in which survival period increased as the dose and frequency of administration increased (Fig. 15) (*p<0.05, **p<0.01, ***<0.001, ns: not significant).

[0196] In terms of weight changes, the tumor-only group and the CBNK (MCB) administration group began to lose weight around day 37, and all animals died on days 56 and 53, respectively. They showed a tendency for weight loss to lead to death as the disease progressed. In the CD5 CAR-NK (MCB) administration group, some animals died without any significant weight loss.

[0197] As a result of imaging measurements, in the CBNK (MCB) administration groups administered once or three times, imaging signals were measured from day 21, whereas no imaging signals were measured in any of the CD5 CAR-NK (MCB) administration groups, confirming a remarkable tumor formation inhibition ability (Fig. 16). Even at day 56, when all CBNK (MCB) administration groups died, the CD5 CAR-NK (MCB) administration group maintained 2 x 10 6 Except for some individuals in the cells / head experimental group, it was confirmed that tumor formation was suppressed. As a result of measuring the image signal value (photon / s), the image signal value of the CBNK (MCB) administration group increased from day 21, whereas the CD5 CAR-NK (MCB) administration group maintained a level similar to the day of tumor administration until day 35 in both the single and triple administration groups (Fig. 16). Even at day 112, the final imaging observation time, it was confirmed that the tumor formation suppression ability was maintained in the surviving individuals in the CD5 CAR-NK (MCB) administration group, and statistical significance was confirmed through one-way analysis of variance (ANOVA) (*p<0.05, **p<0.01, ***<0.001, ****<0.0001, ns: no significance).

[0198] Median survival period Test group Dosage of substance (number of cells per mouse) Median survival period P-value Control group PBS N / A > 137 days Tumor only N / A 51 days (A) CBNK (MCB) 1 x 10 7 50 days 0.0021 (vs. CBNK) CD5 CAR-NK (MCB) 1 x 10 7 129 days (B)CBNK (MCB)1 x 10 7 48 days 0.0018 (vs. CBNK) CD5 CAR-NK (MCB) 1 x 10 7 >137 days(C)CBNK (MCB)1 x 10 7 48 days nsCD5 CAR-NK (MCB) 1 x 10 7 >137 days 0.0036 (vs. CBNK) CD5 CAR-NK (MCB) 5 x 10 6 >137 days 0.0036 (vs. CBNK) CD5 CAR-NK (MCB) 2 x 10 6 100 days 0.0026 (vs. CBNK)

[0199] Results of image signal values ​​(photons / s) according to the number of administrations after tumor administrationA (Photons / s)D0D7D14D21D28D35CBNK(single injection)Average242000460000222000045300003840000049600000SD1950013200094000018500001080000020100000CAR-NK(single injection)Average24300045900020200005590001860000475000SD223001500008740008150084800088400p-valuensnsns0.0047<0.00010.0005CBNK(3 times, weekly) 2 times) Average 243000436000221000052700003180000060800000SD 190001080008260002070000734000030700000p valuensnsnsnsnsnsCAR-NK (3 times, 2 times a week) Average 24300042100020800004890002330000559000SD 3890011400090200025500106000056900p valuensnsns0.004<0.00010.0005CBNK (3 times, (Weekly) Average 243000433000186000062300003240000066300000SD 269001020005030003050000406000018900000p-valuensnsnsnsnsnsCAR-NK (3 times, weekly) Average 24200034000018500006890002760000509000SD 2320011000083500075400142000023900p-valuensnsnsns0.0063<0.00010.0005

[0200] Results of image signal values ​​(photons / s) according to the administered dose after tumor administration B (photons / s) D0 D7 D14 D21 D28 D35 CBNK (10 M / head) Average 243000 433000 1860000 6230000 32400000 66300000 SD 26900102000 503000 3050000 4060000 18900000 CAR-NK (2 M / head) Average 243000 349000 2040000 732000 2580000 673000 SD 29600110000 869000 115000 1330000 148000 p value ns ns 0.0001 < 0.0001 < 0.0001 CAR-NK(5M / head)Average24300042200026700005420002230000669000SD25900117000123000058900893000128000p-valuensnsns<0.0001<0.0001<0.0001CAR-NK(10M / head)Average24200034000018500006890002760000509000SD2320011000083500075400142000023900p-valuensnsns<0.0001<0.0001<0.0001

[0201]

[0202] 7-4) Evaluation of the efficacy of CD5 CAR-NK cells according to culture period in mice

[0203] Through the same process as Example 7-3, general symptoms and body weight changes were measured twice a week for all animals during the test period, and the median survival time was calculated to compare the survival rates according to the culture period (MCB, DP). Images were taken once a week for a total of 17 times (0, 7, 14, 27, 35, 42, 49, 56, 65, 72, 78, 86, 94 100, 107, 118, 126 days from the date of transplantation) starting from the day of cancer cell transplantation. As a result, in the CBNK (MCB) administration group, hind limb paralysis symptoms were confirmed around 40 days in all individuals regardless of the number of administrations, and all individuals died within 2 weeks after the onset of symptoms, and the median survival time was measured to be 49 days, the same as the tumor only group (Table 19). In the CD5 CAR-NK (MCB) administration group, hind limb paralysis first appeared on day 69, and the first mouse died on day 72. In the CD5 CAR-NK (DP) administration group, the first mouse died on day 83, and there were no hind limb paralysis symptoms immediately before death. Afterwards, unlike CBNK (MCB), hind limb paralysis symptoms before death were observed only in some individuals of CD5 CAR-NK (MCB) and CD5 CAR-NK (DP). The median survival time was measured to be 90 days for CD5 CAR-NK (DP), but more than half of the mice in CD5 CAR-NK (MCB) did not die until day 133, so the median survival time could not be calculated (Fig. 18). Therefore, although the median survival time of CD5 CAR-NK (MCB) was longer than that of CD5 CAR-NK (DP), the difference was not statistically significant. However, both CD5 CAR-NK (MCB) and CD5 CAR-NK (DP) showed statistically significant survival improvement compared to CBNK (MCB), and statistical significance was confirmed through the log-rank (mantel-cox) test (*p<0.05, **p<0.01, ***<0.001, ns: no significance).

[0204] In the case of image measurement, in the case of the Tumor only and CBNK (MCB) administration groups, image signals were measured near the hindquarters of the mice from the 14th day, whereas no image signals were measured in any of the CD5 CAR-NK (MCB) administration groups, confirming a remarkable tumor formation inhibition ability (Fig. 19). In the case of the CD5 CAR-NK (DP) administration group, image signals began to be observed on the 35th day after tumor cell administration, and in the case of CD5 CAR-NK (MCB), image signals began to be observed a week later, on the 42nd day. Even on the 49th day when all CBNK (MCB) mice had died, image signals were observed only in some individuals of the CD5 CAR-NK (MCB) and CD5 CAR-NK (DP) administration groups, indicating that tumor formation was suppressed in the CD5 CAR-NK (MCB, DP) administration group compared to CBNK (MCB). Even at the final imaging observation point of 126 days, it was confirmed that the tumor formation inhibition ability was maintained in surviving individuals, and statistical significance was confirmed through one-way ANOVA (*p<0.05, **p<0.01, ***<0.001, ****<0.0001, ns: no significance).

[0205] Median survival periodTest groupAdministration substanceDosageMedian survival periodP-value(NK cell number per mouse)Control groupPBSN / A>133 daysnsTumor onlyN / A49 daysnsExperimental groupCBNK (MCB)1 x 10 7 49 days nsCD5 CAR-NK (MCB) 1 x 10 7 >133 days 0.0016 (vs. CBNK) CD5 CAR-NK (DP) 1 x 10 7 90 days 0.0016 (vs. CBNK)

[0206] While specific aspects of the present invention have been described in detail above, it should be apparent to those skilled in the art that these specific descriptions are merely preferred embodiments and do not limit the scope of the present invention. Therefore, the substantial scope of the present invention is defined by the appended claims and their equivalents.

Claims

1. Fusion proteins containing: (a) a chimeric antigen receptor (CAR) comprising an intracellular signaling domain comprising an OX40 ligand (OX40L); and an extracellular antigen binding domain that binds to CD5; and (b) IL(Interleukin)-15.

2. A fusion protein according to claim 1, characterized in that the extracellular antigen binding domain is an antigen binding fragment of an anti-CD5 antibody.

3. A fusion protein characterized in that in the second paragraph, the antigen-binding fragment is a Fab fragment, an F(ab') fragment, an F(ab')2 fragment, or an Fv fragment.

4. A fusion protein according to claim 2, characterized in that the extracellular antigen binding domain comprises a heavy chain variable region including HCDR1 having an amino acid sequence of sequence number 26, HCDR2 having an amino acid sequence of sequence number 28, and HCDR3 having an amino acid sequence of sequence number 30.

5. A fusion protein according to claim 4, characterized in that the heavy chain variable region comprises an amino acid sequence of sequence number 32.

6. A fusion protein according to claim 2, characterized in that the extracellular antigen binding domain additionally includes a light chain variable region including LCDR1 having an amino acid sequence of sequence number 34, LCDR2 having an amino acid sequence of sequence number 36, and LCDR3 having an amino acid sequence of sequence number 38.

7. A fusion protein according to claim 6, characterized in that the light chain variable region comprises an amino acid sequence of SEQ ID NO:

40.

8. A fusion protein according to claim 2, characterized in that the extracellular antigen binding domain comprises the amino acid sequence of sequence number 7.

9. A fusion protein according to claim 1, characterized in that the intracellular signaling domain additionally comprises one or more domains selected from the group consisting of CD28, CD3-zeta, OX40, and 4-1BB.

10. A fusion protein according to claim 9, characterized in that the intracellular signaling domain additionally includes CD28 and CD3-zeta.

11. A fusion protein according to claim 10, wherein the intracellular signaling domain comprises CD28, OX40L, and CD3-zeta sequentially from the cell membrane to the intracellular direction.

12. A fusion protein according to claim 1, characterized in that the fusion protein additionally comprises a self-cleaving peptide located between the chimeric antigen receptor and the IL-15.

13. A fusion protein according to claim 12, characterized in that the self-cleaving peptide comprises an amino acid sequence of sequence number 21.

14. A nucleic acid molecule encoding a fusion protein of any one of claims 1 to 13.

15. An immune cell expressing the nucleic acid molecule of item 14.

16. Immune cells that express: (a) a chimeric antigen receptor (CAR) comprising an intracellular signaling domain comprising an OX40 ligand (OX40L); and an extracellular antigen binding domain that binds to CD5; and (b) IL(Interleukin)-15.

17. An immune cell according to claim 16, characterized in that the immune cell is a natural killer cell.

18. An immune cell according to claim 17, characterized in that the natural killer cells are natural killer cells that have been cultured for 23 to 35 days and then frozen and thawed.

19. A composition for preventing or treating CD5-positive tumors, comprising the immune cells of claim 15 or 16 as an active ingredient.

20. A composition according to claim 19, characterized in that the CD5 positive tumor is lymphocytic leukemia.